Type: Combined measles, mumps, rubella, and varicella vaccine, live, attenuated
Form: Lyophilized powder for injection
Manufacturer: GlaxoSmithKline Inc.
Indications and Clinical Use
Indication: Active immunization against measles, mumps, rubella, and varicella in individuals from 9 months to 6 years of age. May be used in individuals up to 12 years of age based on previous experience with the component vaccines (PRIORIX and VARILRIX).
Contraindications
Known hypersensitivity to neomycin or any other component of the vaccine.
Severe humoral or cellular immunodeficiency.
Pregnant women (pregnancy should be avoided for one month after vaccination).
Warnings and Precautions
General: Do not administer intravascularly or intradermally. Postpone vaccination in cases of acute severe febrile illness.
Anaphylaxis: Appropriate medical treatment should be available in case of anaphylactic reactions.
Syncope: Procedures should be in place to prevent injury from fainting.
Immune Response: Limited protection may be obtained if vaccinated up to 72 hours post-exposure to natural measles.
Transmission Risk: Pharyngeal excretion of the rubella virus can occur; transmission of the Oka vaccine virus may occur, particularly in vaccinees who develop a rash.
Adverse Reactions
Very Common (≥1/10): Pain and redness at the injection site, fever (rectal ≥38°C and ≤39.5°C; axillary/oral: ≥37.5°C and ≤39°C).
Common (≥1/100 to <1/10): Swelling at the injection site, fever (rectal >39.5°C; axillary/oral >39°C), irritability, rash (measles-like, rubella-like, varicella-like).
Rare (≥1/10,000 to <1/1,000): Injection site bruising, otitis media, febrile convulsions, cough, bronchitis.
Drug Interactions
Can be co-administered with vaccines like hexavalent vaccines (DTaP-HBV-IPV-Hib), diphtheria-tetanus-acellular pertussis vaccine (DTaP), Hib, IPV, HBV, BEXSERO, MenC, MenACWY, and PCV.
Avoid salicylates for 6 weeks post-vaccination due to the risk of Reye’s Syndrome.
Dosage and Administration
Primary Immunization: Two doses, with an interval of at least 6 weeks between doses (not less than 4 weeks).
Route: Subcutaneous (SC) or intramuscular (IM) injection.
Reconstitution: Reconstitute with the provided diluent, inspect for particulates, and administer promptly or within 8 hours if refrigerated.
Storage and Stability
Store at 2°C to 8°C. Do not freeze. Protect from light. Use reconstituted vaccine within 8 hours if stored in a refrigerator.
